MediWound Ltd.
HealthcareNASDAQ:MDWD · NASDAQ Global Market
+$0.13 today
Vol 0.05M · Avg 0.09M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-54.7%
avg -66.3%
ROIC
-41.3%
avg -39.8%
ROA
-27.7%
avg -32.0%
Analysis
ROA is currently the strongest return metric at -27.7% versus its period average of -32.0%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Ofer Gonen | Chief Executive Officer | $834,000.00 | — | 53 | $35,714.00 | 0.33% |
Ety Klinger | Chief Medical Officer | $428,000.00 | — | 64 | $2,828.00 | 0.03% |
Shmulik Hess | Chief Operating Officer & Chief Commercial Officer | $426,000.00 | — | 52 | $4,085.00 | 0.04% |
Hani Luxenburg | Chief Financial Officer | $420,000.00 | — | 52 | $4,085.00 | 0.04% |
Yaron Meyer Adv. | Executive Vice President, General Counsel & Corporate Secretary | $337,000.00 | — | 47 | $2,357.00 | 0.02% |
Liron Gal | Vice President of Manufacturing Science & Technology | — | — | — | — | — |
Robert J. Snyder FFPM | Senior Vice President of Global Medical Affairs | — | — | 75 | — | — |
Hagit Mashiach | Vice President of Human Resources | — | — | — | — | — |
Barry J. Wolfenson | Executive Vice President of Strategy & Corporate Development | — | — | 59 | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
6
$136,045.69
Sells
0
$0.00
Net Sentiment
+$136,045.69
Net buying
Most Active
Fox David Morton
3 transactions
Analysis
Insiders reported 6 buys worth $136,045.69 and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $136,045.69. Fox David Morton was the most active insider with 3 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | +45.6% (15yr)1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Forward estimates point to Revenue at +45.6% (15yr), giving you a quick read on expected growth from here.
Competitors
Peer companies in the same sector
SELLAS Life Sciences Group, Inc.
NASDAQ:SLS
$1.12B
Genfit S.A.
GNFT
$445.68M
Cartesian Therapeutics, Inc.
NASDAQ:RNAC
$279.42M
Orchestra BioMed Holdings, Inc.
NASDAQ:OBIO
$245.51M
Eupraxia Pharmaceuticals Inc.
NASDAQ:EPRX
$202.22M
Inventiva S.A.
NASDAQ:IVA
$200.13M
Protara Therapeutics, Inc.
NASDAQ:TARA
$150.50M
Invivyd, Inc.
NASDAQ:IVVD
$102.20M
Neonc Technologies Holdings, Inc.
NASDAQ:NTHI
$94.98M
Aardvark Therapeutics, Inc. Common Stock
NASDAQ:AARD
$85.08M
Who manages MDWD?
MediWound Ltd. (MDWD) lists 9 active executives. The top listed executive is Liron Gal, Vice President of Manufacturing Science & Technology.
Are MDWD insiders buying or selling?
Recent insider activity shows net buying of $136,045.69.
Explore More
Continue the stock analysis
Jump to another research area for this company.